Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer

被引：0
|
作者：
Goyal, R. K.
Carter, G. C.
Nagar, S. N.
Smyth, E. N.
Price, G. L.
Huang, Y-J
Bromund, J. L.
Li, L.
Schilder, J. M.
Davis, K. L.
Kaye, J. A.
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] RTI Hlth Solut, Waltham, MA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-08-19
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] Treatment patterns and resource utilization among patients with HR+/HER2-metastatic breast cancer in a privately insured US population
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
  • [2] Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2-metastatic breast cancer
    Goyal, Ravi K.
    Carter, Gebra Cuyun
    Nagar, Saurabh P.
    Smyth, Emily N.
    Price, Gregory L.
    Huang, Yu-Jing
    Li, Li
    Davis, Keith L.
    Kaye, James A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (10) : 1699 - 1710
  • [3] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Real-world treatment patterns, healthcare resource utilization and costs of care among newly-diagnosed patients with HR+/HER2-metastatic breast cancer
    Basho, Reva K.
    Ng, Carmen
    Dillon, Allison
    Chen, Lu
    Cheng, Anna
    Du Toit, Yolande
    Abbass, Ibrahim M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    CANCER RESEARCH, 2016, 76
  • [6] Physician survey in the treatment of HR+/HER2-metastatic breast cancer in Egypt
    Aboelkheir, E.
    Ashour, A.
    Fadel, S.
    Arafat, W.
    BREAST, 2021, 56 : S31 - S31
  • [7] Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2-metastatic breast cancer
    Carter, Gebra Cuyun
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Smith, Emily Nash
    Mathur, Raina
    Cohen, Aaron B.
    Baxi, Shrujal
    Rybowski, Sarah
    Chong, Amy Lee
    Seidman, Andrew D.
    CANCER RESEARCH, 2020, 80 (04)
  • [8] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [9] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer
    Cuyun Carter, Gebra
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Nash Smyth, Emily
    Mathur, Raina
    Cohen, Aaron B.
    Rasmussen, Erik
    Balakrishna, Shreya
    Morato Guimaraes, Claudia
    Rybowski, Sarah
    Seidman, Andrew D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) : 1179 - 1187
  • [10] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
12345